Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
AVTX
AVTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AVTX News
Avalo Therapeutics Completes Enrollment for AVTX-009 Trial
Feb 02 2026
Benzinga
Valvoline Analyst Starts Coverage Optimistically; Check Out Thursday's Top 5 Initiations
Dec 18 2025
Benzinga
Avalo Therapeutics Reveals Inducement Grants for New Hires in Accordance with Nasdaq Listing Rule 5635(c)(4)
Nov 17 2025
Newsfilter
Avalo Therapeutics Completes Patient Enrollment in Phase 2 LOTUS Trial for AVTX-009 Targeting Hidradenitis Suppurativa Treatment
Oct 29 2025
Newsfilter
DFAS's Assets May Indicate a 15% Profit Opportunity
Oct 02 2025
NASDAQ.COM
Avalo Therapeutics Strengthens Leadership Team with Important New Hires in Business Development and HR
Oct 01 2025
Newsfilter
Merus Shares Surge 38%; Check Out 20 Stocks Making Moves in Premarket Trading
Sep 29 2025
Benzinga
Avalo Therapeutics Names Kevin R. Lind to Its Board of Directors
Sep 22 2025
Newsfilter
HC Wainwright & Co. Reaffirms Buy Rating for Avalo Therapeutics, Increases Price Target to $25
Sep 17 2025
Benzinga
Top Analysts Recommend 3 Best Stocks to Purchase Now, 9/12/2025
Sep 12 2025
TipRanks
Top Analysts Recommend 3 Best Stocks to Purchase Now, 9/5/2025
Sep 05 2025
TipRanks
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
Aug 07 2025
Newsfilter
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
Jun 18 2025
Newsfilter
HC Wainwright & Co. Assumes Avalo Therapeutics at Buy, Announces Price Target of $15
Jun 02 2025
Benzinga
Avalo Therapeutics to Participate in Upcoming Investor Conferences
May 27 2025
Newsfilter
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Mar 26 2025
Newsfilter
Show More News
